circle

A PIPELINE POWERED BYPASSION

PUBLICATIONS AND PRESENTATIONS

Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure

JAMA Cardiology
Felker GM, Solomon SD, Claggett B, et al
October 13, 2021

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Journal of Medicinal Chemistry
Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, Jamison CR, Lu K, Lu P, et al.
October 12, 2021

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Journal of Medicinal Chemistry
Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzy J, Wehri E, Robertson LA, Malik FI, Morgan BP
October 4, 2021

REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy

Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Maron, M, et al
Denver, CO
September 12, 2021

Effect of Omecamtiv Mecarbil in Black Patients with Heart Failure and Reduced Ejection Fraction

Presentation, Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Lanfear, DE, et al
Denver, CO
September 12, 2021